Long-term Study of Romiplostim in Thrombocytopenic Pediatric Patients With Immune Thrombocytopenia (ITP)
Status:
Completed
Trial end date:
2019-08-08
Target enrollment:
Participant gender:
Summary
This is a phase 3b single arm, open label, multicenter study describing the percentage of
time pediatric participants with ITP have a platelet response while receiving romiplostim,
defined as a platelet count ≥ 50 x 10^9/L in the absence of ITP rescue medications for the
past 4 weeks.